{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:21:58Z","timestamp":1771006918461,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":1396,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ek0109367h0003"],"award-info":[{"award-number":["20ek0109367h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19ek0109367h0002"],"award-info":[{"award-number":["19ek0109367h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1051"],"award-info":[{"award-number":["20FC1051"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ek0109367h0003"],"award-info":[{"award-number":["20ek0109367h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19ek0109367h0002"],"award-info":[{"award-number":["19ek0109367h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1051"],"award-info":[{"award-number":["20FC1051"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Angiotensin-converting enzyme inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) have been shown to be associated with recovery of cardiac function in patients with dilated cardiomyopathy (DCM). The aim of this study was to assess comparative effectiveness of ACEis vs. ARBs on recovery of left ventricular ejection fraction (LVEF) among patients with DCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We analysed the clinical personal records of DCM, a national database of the Japanese Ministry of Health, Labour and Welfare, from 2003 to 2014. Patients with LVEF &amp;lt; 40% and on either ACEis or ARBs were included. Eligible patients were divided into two groups according to the use of ACEis or ARBs. A one-to-one propensity case-matched analysis was used. The primary outcome was defined as LVEF \u2265 40% at 3 years of follow-up. Out of 4618 eligible patients, 2238 patients received ACEis and 2380 patients received ARBs. Propensity score matching yielded 1341 pairs. Mean age was 56.0 years, 2041 (76.1%) were male, median duration of heart failure was 1 year, and mean LVEF was 27.6%. The primary outcome was observed more frequently in ARB group than in ACEi group (59.8% vs. 54.1%; odds ratio 1.26; 95% confidence interval 1.08\u20131.47; P = 0.003). The per-protocol analysis showed similar results (62.0% vs. 54.0%; odds ratio 1.39; 95% confidence interval 1.17\u20131.66; P &amp;lt; 0.001). The change in LVEF from baseline to 3 years of follow-up was greater in ARB group than in ACEi group (15.8 \u00b1 0.4% vs. 14.0 \u00b1 0.4%, P = 0.003). The subgroup analysis showed that this effect was observed independently of systolic blood pressure, heart rate, LVEF, chronic kidney disease, and concomitant use of beta-blockers and mineralocorticoid receptor antagonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of ARBs was associated with LVEF recovery more frequently than ACEis among patients with DCM and reduced LVEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.13790","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T02:47:48Z","timestamp":1644374868000},"page":"1175-1185","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Use of Angiotensin II Receptor Blocker is Associated with Greater Recovery of Cardiac Function than Angiotensin-Converting Enzyme Inhibitor in Dilated Cardiomyopathy"],"prefix":"10.1093","volume":"9","author":[{"given":"Nobuyuki","family":"Enzan","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University , Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shouji","family":"Matsushima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University , Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Ide","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University , Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Tohyama","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Kyushu University Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouta","family":"Funakoshi","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Research, Kyushu University Hospital , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiki","family":"Higo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Hospital Organization, Kyushu Medical Center , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University , Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"2026012114170354900_ehf213790-bib-0001","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2026012114170354900_ehf213790-bib-0002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2026012114170354900_ehf213790-bib-0003","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2026012114170354900_ehf213790-bib-0004","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114170354900_ehf213790-bib-0006","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114170354900_ehf213790-bib-0007","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"2026012114170354900_ehf213790-bib-0008","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2026012114170354900_ehf213790-bib-0009","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0010","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026012114170354900_ehf213790-bib-0011","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"2026012114170354900_ehf213790-bib-0012","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.amjcard.2011.06.066","article-title":"A propensity-matched study of the comparative effectiveness of angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors in heart failure patients age \u226565 years","volume":"108","author":"Zhang","year":"2011","journal-title":"Am J Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0013","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/CIRCRESAHA.117.309711","article-title":"Classification, epidemiology, and global burden of cardiomyopathies","volume":"121","author":"McKenna","year":"2017","journal-title":"Circ Res"},{"key":"2026012114170354900_ehf213790-bib-0014","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1253\/circj.70.376","article-title":"Long-term prognosis of dilated cardiomyopathy revisited: an improvement in survival over the past 20 years","volume":"70","author":"Matsumura","year":"2006","journal-title":"Circ J"},{"key":"2026012114170354900_ehf213790-bib-0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/jcp.2008.060731","article-title":"Dilated cardiomyopathy: a review","volume":"62","author":"Luk","year":"2009","journal-title":"J Clin Pathol"},{"key":"2026012114170354900_ehf213790-bib-0016","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1755-5922.2010.00247.x","article-title":"Myocardial reverse remodeling","volume":"30","author":"Hellawell","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"2026012114170354900_ehf213790-bib-0017","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cardfail.2011.03.005","article-title":"Heart failure with recovered ejection fraction: a distinct clinical entity","volume":"17","author":"Punnoose","year":"2011","journal-title":"J Card Fail"},{"key":"2026012114170354900_ehf213790-bib-0018","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.116.003123","article-title":"Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the Valsartan Heart Failure Trial","volume":"9","author":"Florea","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026012114170354900_ehf213790-bib-0019","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1001\/jamacardio.2016.1325","article-title":"Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction","volume":"1","author":"Kalogeropoulos","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0020","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/2047487317750437","article-title":"Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: a systematic review and meta-analyses","volume":"25","author":"Jorgensen","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011077","article-title":"Characteristics, outcomes, and treatment of heart failure with improved ejection fraction","volume":"8","author":"Park","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026012114170354900_ehf213790-bib-0022","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray","year":"2014","journal-title":"Circulation"},{"key":"2026012114170354900_ehf213790-bib-0023","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0024","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.amjcard.2005.05.037","article-title":"Reliability of ventricular remodeling as a surrogate for use in conjunction with clinical outcomes in heart failure","volume":"96","author":"Konstam","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(02)02063-6","article-title":"Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study","volume":"40","author":"Wong","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0026","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1536\/ihj.20-671","article-title":"The use of angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers is associated with the recovered ejection fraction in patients with dilated cardiomyopathy","volume":"64","author":"Enzan","year":"2021","journal-title":"Int Heart J"},{"key":"2026012114170354900_ehf213790-bib-0027","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0002-9149(01)02261-5","article-title":"Relation of aldosterone \u201cescape\u201d despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy","volume":"89","author":"Cicoira","year":"2002","journal-title":"Am J Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0028","doi-asserted-by":"crossref","first-page":"1L","DOI":"10.1016\/S0002-9149(01)01878-1","article-title":"The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data","volume":"88","author":"Dzau","year":"2001","journal-title":"Am J Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0029","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"2026012114170354900_ehf213790-bib-0030","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0031","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/ejhf.824","article-title":"Recovered heart failure with reduced ejection fraction and outcomes: a prospective study","volume":"19","author":"Lupon","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114170354900_ehf213790-bib-0032","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1253\/circrep.CR-21-0001","article-title":"Clinical characteristics and contemporary management of patients with cardiomyopathies in Japan\u2014report from a national registry of clinical personal records","volume":"3","author":"Enzan","year":"2021","journal-title":"Circ Rep"},{"key":"2026012114170354900_ehf213790-bib-0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0962280217713032","article-title":"Propensity score analysis with partially observed covariates: how should multiple imputation be used?","volume":"28","author":"Leyrat","year":"2019","journal-title":"Stat Methods Med Res"},{"key":"2026012114170354900_ehf213790-bib-0034","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ijcard.2015.07.051","article-title":"Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction","volume":"199","author":"Savarese","year":"2015","journal-title":"Int J Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ahj.2011.10.001","article-title":"Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF","volume":"163","author":"Wilcox","year":"2012","journal-title":"Am Heart J"},{"key":"2026012114170354900_ehf213790-bib-0036","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.joa.2016.04.002","article-title":"Trends and determinant factors in the use of cardiac resynchronization therapy devices in Japan: analysis of the Japan cardiac device treatment registry database","volume":"32","author":"Yokoshiki","year":"2016","journal-title":"J Arrhythm"},{"key":"2026012114170354900_ehf213790-bib-0037","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0735-1097(97)00087-9","article-title":"Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart","volume":"29","author":"Morris","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0038","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0002-9149(99)80413-5","article-title":"Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension","volume":"75","author":"Goldberg","year":"1995","journal-title":"Am J Cardiol"},{"key":"2026012114170354900_ehf213790-bib-0039","doi-asserted-by":"crossref","first-page":"E14","DOI":"10.1161\/hc3001.094733","article-title":"Manipulation of the renin-angiotensin system","volume":"104","author":"Givertz","year":"2001","journal-title":"Circulation"},{"key":"2026012114170354900_ehf213790-bib-0040","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/s41598-018-20114-9","article-title":"Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling","volume":"8","author":"Tobita","year":"2018","journal-title":"Sci Rep"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.13790","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.13790","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/2\/1175\/65375489\/eschf_9_2_1175.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/9\/2\/1175\/65375489\/eschf_9_2_1175.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:20:25Z","timestamp":1769023225000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/9\/2\/1175\/8326222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,8]]},"published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.13790","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4]]},"published":{"date-parts":[[2022,2,8]]},"assertion":[{"value":"2021-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}